Trusted Resource for Clinical Trials, Protocols & Progress
Biomarkers are measurable indicators of biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In the realm of clinical trials, biomarkers are pivotal for improving trial efficiency, optimizing patient stratification, and supporting regulatory decisions. They serve multiple roles such as diagnostic, prognostic, predictive, and surrogate endpoints.
Click to read the full article.
Genomic profiling has become a cornerstone in the discovery and application of clinical biomarkers. It enables researchers to examine the complete genetic landscape of individuals or tumor cells to identify variations that predict disease progression, drug response, or toxicity. This powerful tool supports the development of personalized therapies and companion diagnostics that align with the goals of precision medicine.
Click to read the full article.
Proteomics—the large-scale study of proteins—plays a pivotal role in the identification of novel biomarkers for clinical applications. Unlike genomics, which captures potential biological behavior, proteomics reflects the actual functional state of cells and tissues. Since most therapeutic targets and diagnostic markers are proteins, proteomics serves as a direct link between genotype and phenotype in disease.
Click to read the full article.
Imaging biomarkers are quantifiable characteristics extracted from medical images that indicate normal biological processes, pathogenic processes, or responses to therapeutic interventions. Unlike molecular biomarkers which require blood or tissue samples, imaging biomarkers provide non-invasive, spatial, and temporal insights into disease evolution.
Click to read the full article.
Liquid biopsy refers to the non-invasive analysis of tumor-derived material from body fluids, especially blood. This technique has emerged as a transformative tool in oncology, enabling real-time tumor monitoring without the need for surgical or tissue biopsies. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomal RNA, clinicians can detect genetic mutations, monitor treatment response, and assess minimal residual disease (MRD).
Click to read the full article.
Biomarkers are powerful tools in precision medicine, aiding in diagnosis, prognosis, treatment stratification, and monitoring. However, their translational success heavily depends on their reproducibility and validation across clinical settings. Reproducibility ensures that a biomarker performs consistently across different populations, laboratories, and study phases—an essential requirement for regulatory approval and clinical adoption.
Click to read the full article.
Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, and amyotrophic lateral sclerosis (ALS) pose significant challenges for diagnosis, monitoring, and therapeutic evaluation. Biomarkers are increasingly essential in these areas, enabling early detection, disease stratification, and treatment efficacy assessments.
Click to read the full article.
Biomarkers hold immense potential in revolutionizing diagnostics, treatment stratification, and monitoring. However, their discovery and application raise complex ethical questions. From genetic risk prediction to incidental findings, biomarker research intersects with deeply personal, societal, and legal issues that must be addressed through sound ethical frameworks.
Click to read the full article.
Artificial intelligence (AI) has emerged as a transformative force in biomedical research, particularly in biomarker discovery and validation. With the exponential growth of omics data—genomics, proteomics, transcriptomics—AI and machine learning (ML) tools are essential for identifying, ranking, and validating biomarkers that would otherwise remain hidden in vast datasets.
Click to read the full article.
Biomarker discovery and validation are complex, resource-intensive processes that often exceed the capacity of individual institutions. To overcome scientific, logistical, and regulatory hurdles, global research communities have embraced collaborative networks. These alliances bring together academia, industry, government, and non-profit sectors to share data, infrastructure, and insights—accelerating the journey from biomarker identification to clinical implementation.
Click to read the full article.
